RMC-4550 is a potent and selective SHP2 allosteric inhibitor. RMC-4550 was identified through a biochemical and cellular screen of compounds and a subsequent structure-guided medicinal chemistry campaign to optimize potency, selectivity and drug-like properties (Fig. 1a ). RMC-4550 is an allosteric inhibitor of SHP2 and stabilizes the auto-inhibited conformation of wild-type SHP2 enzyme 17 , with a mode of inhibition similar to that described previously for SHP099 16, 18 . Consistent with an allosteric mode of inhibition, RMC-4550 inhibited the activity of full-length wild-type SHP2 enzyme activated by a di-phosphotyrosine peptide, but lacked activity against the free catalytic domain of SHP2 (Fig. 1b ). In addition, the potency of RMC-4550 was significantly reduced in the setting of the hyperactive mutant SHP2 E76K or an established allosteric binding site mutant, SHP2 T253M/Q257L (ref. 16 ; Fig. 1c ). RMC-4550 potently inhibited pERK levels driven by the oncogenic EGFR exon19deletion in PC9 cells, and by EGF stimulation in HEK293 cells (Fig. 1d,e ). In the isogenic HEK293 system, inhibition of pERK levels by RMC-4550 was rescued by expression of either SHP2 E76K or the allosteric binding site mutant, establishing an on-target effect of the drug against SHP2 (Fig. 1e ). In addition, RMC-4550 was highly selective for full-length SHP2 over other phosphatase, kinase, and safety pharmacology targets ( Supplementary Tables 1-3 ).
O ncogenic activation of the RAS/MAPK signalling pathway occurs across a wide spectrum of tumour types 1 . Tumourdriving hyperactivation of RAS/MAPK signalling arises via disruption of the RAS guanine nucleotide exchange cycle and its regulation by RAS guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs), which control the levels of active GTP-bound RAS in cells 2 . Among the tumour types with widespread hyperactivation of RAS/MAPK signalling is non-small cell lung cancer (NSCLC), in which oncogenic RAS/MAPK pathway activation is caused by mutations in KRAS or in upstream or downstream components of the pathway such as receptor tyrosine kinases (RTKs) or BRAF 3 . Inactivation of the tumour suppressor gene neurofibromin 1 (NF1), which encodes a RAS GAP, is an additional mechanism driving dysregulated RAS signalling in multiple tumour types, including approximately 10% of NSCLCs 4, 5 . Despite extensive clinical evaluation of RAF and MEK inhibitors across multiple tumour histologies harbouring oncogenic mutations in RAS or RAF 6 , only tumours driven by BRAF V600 mutations have shown consistent clinical responses 7 . Identifying new therapeutic strategies to block RAS/MAPK pathway signalling and growth in tumours with oncogenic activation of the pathway is of paramount importance.
A commonly accepted paradigm is that proteins with driver mutations in the RAS/MAPK pathway are constitutively active and function independently of normal upstream regulation. This is exemplified by the BRAF V600E oncoprotein, which signals as a monomer in a RAS-GTP-independent fashion. However, the recently described class 3 mutants of BRAF do not directly hyperactive BRAF kinase activity and instead promote RAF hetero-dimerization and signalling in a RAS-GTP-dependent manner and therefore require upstream signals to drive aberrant cell growth 8,9 . In addition, recent studies have demonstrated that some oncogenic mutant allelotypes of KRAS, such as G12C, undergo active cycling between GTP-and GDP-bound states and therefore remain sensitive to modulation by upstream pathway components [10] [11] [12] . These oncogenic variants appear to amplify physiologic growth signals rather than drive signalling autonomously. SHP2 (encoded by PTPN11) is a non-receptor protein tyrosine phosphatase and scaffold protein that functions downstream of multiple RTKs, integrating growth factor signals to promote RAS activation 13 . Autosomal dominant activating mutations in PTPN11 fuel excess RAS/MAPK signalling that drives certain human RASopathies and cancers 14, 15 . Genetic knockdown or pharmacological inhibition of SHP2 suppresses RAS/MAPK signalling and has been shown to limit the proliferation of cancer cells dependent on a range of activated RTKs 16 .
Here, we describe a potent and selective SHP2 allosteric inhibitor, RMC-4550, and use this inhibitor to test the hypothesis that SHP2 is required for RAS activation and proliferation in cancers that are driven by RAS/MAPK pathway oncogenic mutants (beyond Purified full-length SHP2 was incubated with di-phosphotyrosine peptide and inhibitor for 30 min before determining the initial rate of substrate (DiFMUP) hydrolysis. The assay conditions for the SHP2 catalytic domain were identical but omitted peptide. RMC-4550 and SHP099 produced a concentration-dependent reduction in the activity of full-length SHP2 but had no effect on the catalytic domain up to the maximum test concentrations of 3 μ M (RMC-4550) and 10 μ M (SHP099). Geometric mean half-maximum inhibitory concentration (IC 50 ) values for RMC-4550 and SHP099 were 0.583 nM and 53.7 nM (RMC-4550 n = 8 independent experiments; SHP099 n = 6 independent experiments; the data represent the mean ± s.d.) c, Effect of RMC-4550 on full length wild-type (WT) SHP2, SHP2 E76K or SHP2 T253M/Q257L . The phosphatase activity of all enzymes was assayed as described in b. RMC-4550 produced a concentrationdependent reduction in the activity of wild-type SHP2 but had a greatly reduced effect in the E76K or T253M/Q257L mutants (SHP2 WT n = 8 independent experiments, SHP2 E76K n = 3 independent experiments, SHP2 T253M/Q257L n = 3 independent experiments; the data represent the mean ± s.d.). d, PC9 cells were grown in 2D culture and incubated with increasing concentrations of RMC-4550 or erlotinib for 1 h before determining pERK levels. RMC-4550 produced a concentration-dependent reduction in pERK with a geometric mean IC 50 value of 31 nM (n = 4 independent experiments; the data represent the mean ± s.d.). e, Effect of RMC-4550 on HEK293 cells expressing wild-type SHP2, SHP2 E76K or SHP2 T253M/Q257L . Isogenic HEK293 cell lines expressing each SHP2 variant were incubated with RMC-4550 for 1 h, stimulated with EGF for 5 min, lysed and the levels of pERK were determined. RMC-4550 produced a concentration-dependent reduction in the level of pERK in cells expressing wild-type SHP2 with a geometric mean IC 50 value of 49.2 nM (n = 4 independent experiments; the data represent the mean ± s.d.). No inhibitory activity was observed in cells expressing E76K or T253M/Q257L mutants up to the maximum test concentration of 10 μ M. Source data are provided in Supplementary Table 9 .
Class 3 BRAF mutant cell lines are sensitive to SHP2 inhibition.
To determine whether specific driver mutations in proteins downstream of SHP2 in the RAS/MAPK pathway are sensitive to SHP2dependent regulation of RAS-GTP levels, we screened a collection of cancer cell lines carrying diverse oncogenic mutations. BRAF is a serine/threonine kinase that is frequently mutated in human cancers. There are at least three classes of oncogenic BRAF mutations that each differ in the mechanism by which they drive pERK signalling. Class 1 mutations occur at Val 600 and result in constitutively active monomers of BRAF that decouple BRAF from RAS-GTP activity 19 . Class 2 mutations preserve BRAF's dependence on dimerization, but also decouple dimer-dependent signalling from RAS-GTP levels 20 . We predicted that cancer cell lines driven by either class 1 or class 2 mutations in BRAF would be insensitive to SHP2 inhibition. In contrast, the recently described class 3 mutations of BRAF maintain RAF dimer and RAS-GTP dependence to drive pERK signalling 9 . In light of their dependence on RAS-GTP, we hypothesized that class 3 mutations of BRAF would be responsive to suppression of RAS-GTP levels by SHP2 inhibition. To test these predictions, we screened a representative panel of cell lines bearing oncogenic BRAF mutations across these three classes for sensitivity to SHP2 inhibition. We confirmed that class 1 and 2 BRAF mutations are refractory to SHP2 inhibition ( Fig. 2a-c) . Consistent with the mechanistic framework described above, we observed that RMC-4550 did not inhibit pERK levels or proliferation in BRAF V600E mutant A-375 cells. Similar results were observed in the NCI-H1755 (lung, BRAF G469A ) cell line carrying a class 2 BRAF mutation (G469A), which exhibits RAS-independent homodimer formation and signalling 20 . Notably, RMC-4550 did not inhibit RAS-GTP levels in these cell lines. Class 1 and class 2 BRAF mutant oncoproteins function downstream of RAS but drive strong, ERK-dependent negative feedback that, through mechanisms upstream of RAS, leads to suppression of RAS-GTP 21 . Any residual activation of RAS that occurs in the presence of such negative feedback may be either insensitive to SHP2 inhibition, for example if suppression has occurred via direct inhibition of SOS1 22, 23 , or below the level of detection for our RAS-GTP assay ( Supplementary Fig. 1 ).
In contrast, treatment with RMC-4550 led to suppression of both RAS-GTP and pERK levels in three cell lines carrying class 3 BRAF mutations, NCI-H1666 (BRAF G466V/+ ), NCI-H508 (BRAF G596R/+ ) and CAL-12T (BRAF G466V/+ ) ( Fig. 2e,f ). In the NCI-H1666 and NCI-H508 cells, pathway suppression translated to inhibition of cellular proliferation, while a disconnect was observed in CAL-12T, suggesting the potential presence of additional molecular alterations driving parallel growth and survival pathways in this cell line ( Fig. 2d ). Consistent with the results obtained in the isogenic HEK293 system, expression of the hyperactive variant SHP2 E76K was sufficient to rescue NCI-H508 cells from RMC-4550 ( Supplementary Fig. 2a,b ). These results are consistent with recent reports that class 3 BRAF mutations are bona fide cancer driver alterations that remain sensitive to modulation of upstream signalling and RAS-GTP levels 8, 9 . Therefore, while class 1 and 2 BRAF mutations confer resistance to SHP2 inhibition, class 3 BRAF mutations are RAS/MAPK pathway oncoproteins that can be targeted through upstream blockade of RAS-GTP loading via SHP2 inhibition.
Loss of the tumour suppressor NF1 confers sensitivity to SHP2
inhibition. NF1 is a tumour suppressor and a RAS GAP. Loss of NF1 function has been shown to increase RAS-GTP levels, hyperactivate RAS/MAPK signalling, and contribute to a variety of human cancers 4, 5, 24 . As the increase in RAS-GTP levels is due to loss of RAS GAP function 25 and wild-type RAS retains intrinsic, NF1-independent, GTPase activity 26 , we hypothesized that inhibition of RAS-GTP loading would offset the loss of RAS GAP activity and inhibit RAS-mediated downstream oncogenic signalling. Therefore, we tested whether NF1 LOF cell lines were sensitive to SHP2 inhibition.
Consistent with our hypothesis, proliferation of five out of eight NF1 LOF cell lines exhibited sensitivity to RMC-4550 ( Fig. 3a and Supplementary Table 4 ). Treatment of the sensitive NF1 LOF cell lines NCI-H1838 (lung, NF1 N184fs ) and MeWo (melanoma, NF1 Q1336* ) with RMC-4550 led to downregulation of RAS-GTP levels and suppression of pERK ( Fig. 3b ,c), demonstrating that SHP2 inhibition can attenuate the accumulation of RAS-GTP, and consequent RAS/ MAPK pathway activation resulting from NF1 loss. Expression of SHP2 E76K rescued NCI-H1838 cells from RMC-4550, supporting an on-target effect ( Supplementary Fig. 2c,d ). Corroborating these observations, short hairpin RNA (shRNA) knockdown of NF1 in BEAS-2B non-malignant bronchial epithelial cells resulted in accumulation of RAS-GTP that was attenuated by treatment with RMC-4550 ( Supplementary Fig. 3a ). Collectively, these data indicate that loss of NF1 is a second class of oncogenic mutation that can be targeted through suppression of RAS-GTP loading via SHP2 inhibition.
No effect of SHP2 inhibition was observed in YUHEF (NF1 Q853*/FS-indel ), YUTOGS (NF1 L446F/K2535* ) or M308 (NF1 Q1070* ) melanoma cell lines. The genomic landscape of these lines mirrors that of clinical melanoma populations, in that NF1 LOF mutations frequently occur in cancers that also contain mutations in other RAS/MAPK pathway genes, some of which may confer resistance to SHP2 inhibition 4, 24 . Specifically, M308 cells carry a BRAF V600E mutation, which we observe to drive resistance to SHP2 inhibition. YUTOGS cells lack other known activating mutations in the pathway, but carry the melanoma hotspot mutation RAC1 P29S , which has been shown to confer resistance to BRAF inhibition 27 . YUHEF carries three SOS1 mutations and RAF1 P261L , a previously described MAPK pathway-activating Noonan syndrome mutation 4, 28 . The mechanisms of resistance to SHP2 inhibition warrant further investigation in future studies.
Certain KRAS G12 mutant oncoproteins are dependent on SHP2 for activation. Next, we investigated whether specific driver mutations in KRAS itself may depend on upstream factors for activation and thus be sensitive to SHP2 inhibition. We screened a panel of 33 KRAS-mutant cancer cell lines for sensitivity to RMC-4550 using an in vitro three-dimensional (3D) cell proliferation assay, as KRAS dependence is well known to be more readily revealed in 3D than 2D culture formats 12, [29] [30] [31] (Supplementary Table 5 ). Strikingly, cancer cell lines bearing missense mutations in KRAS at Gly 12, but neither Gly 13 nor Gln 61, exhibited sensitivity to RMC-4550 (GI 50 < 2 μ M, Supplementary Table 5 ). The observation that cancer cell lines bearing the G12C mutation were preferentially sensitive to SHP2 inhibition (hypergeometric P value = 0.0043) extends previous work demonstrating that the sensitivity of KRAS G12C cancer cell lines to a selective KRAS G12C inhibitor can be modulated by upstream signals that regulate RAS activity [10] [11] [12] . In addition, KRAS G12A mutant cell lines were sensitive to SHP2 inhibition, while cell lines bearing KRAS G12V and G12D mutations exhibited a range of responses. These data suggest that certain cancers bearing other oncogenic KRAS variants, beyond KRAS G12C , may also be sensitive to modulation by upstream factors 32, 33 .
In NCI-H358 (lung, KRAS G12C/+ ) and MIA PaCa-2 (pancreas, KRAS G12C/G12C ) cell lines, RMC-4550 treatment inhibited cell proliferation, RAS-GTP and pERK levels (Fig. 4a,b and Supplementary  Fig. 1 ). As predicted, expression of the RMC-4550-insensitive variant SHP2 E76K was sufficient to rescue both the pERK signalling and growth inhibition caused by RMC-4550 treatment ( Supplementary  Fig. 2e ,f). To characterize further the cellular effects of RMC-4550, we examined a marker of apoptosis. In NCI-H358 cells, treatment of 3D spheroid cultures with RMC-4550 led to caspase 3/7 activation, indicating a pro-apoptotic effect (Fig. 4c) . These results support a model in which SHP2 functions upstream of certain nucleotidecycling forms of oncogenic KRAS to regulate its activation by promoting or sustaining GTP loading of RAS. Consistent with this model, genetic knockdown of SHP2 or SOS1 phenocopied RMC-4550 treatment ( Supplementary Fig. 3b-d ).
The proliferation of two KRAS G12C cell lines, NCI-H2122 (lung, KRAS G12C/G12C ) and Calu-1 (lung, KRAS G12C/G12C ), was insensitive to SHP2 inhibition. In Calu-1 cells, RMC-4550 suppressed pERK with a potency comparable to that observed in a sensitive cell line (that is, NCI-H358), confirming inhibition of RAS/MAPK pathway activation by the compound ( Supplementary Fig. 3e ,f). Comparison of the growth sensitivities of these two lines to the KRAS G12C -specific covalent inhibitor ARS-853 12 revealed a similar pattern to the SHP2 inhibitor, and a similar disconnect between signalling pathway and growth inhibition ( Supplementary Fig. 3g ,h). Collectively, these data suggest that the differential sensitivity to growth inhibition across different KRAS G12C -bearing cell lines may reflect intrinsic variability in the dependence of each cell line on KRAS G12C . Indeed, analysis of KRAS-dependencies derived from Project DRIVE 34, 35 revealed a significant correlation between KRAS-dependence and RMC-4550 sensitivity within KRAS G12C and KRAS G12A mutant cell lines (correlation coefficient = 0.36, Supplementary Fig. 4a ). This relationship was not apparent for KRAS mutations outside G12C and G12A, suggesting factors other than KRAS independence may render cells insensitive to SHP2 inhibition in these genotypes. Analysis of a panel of isogenic RASless MEFs transduced with different KRAS mutations 36 were determined. RMC-4550 had no effect on cellular RAS-GTP or pERK levels in either cell line up to the maximal test concentration of 10 μ M. The RAS-GTP data represent the mean ± s.e.m. of n = 4 independent biological experiments. The pERK data are representative of n = 4 independent biological experiments each performed in duplicate; the data represent the mean ± s.d. d, The effect of RMC-4550 on the proliferation of three class 3 BRAF mutant cell lines (CAL-12T, BRAF G466V/+ ; NCI-H1666, BRAF G466V/+ ; NCI-H508, BRAF G596R/+ ) in 3D culture. RMC-4550 exhibited geometric mean IC 50 values of > 10 μ M, 304 nM and 19 nM, respectively, for growth inhibition in CAL-12T, NCI-H1666 and NCI-H508 cells (the data are representative of n = 4 independent biological experiments each performed in duplicate; the data represent the mean ± s.d.). e,f, CAL-12T, NCI-H1666 and NCI-H508 cells were grown in 2D culture and incubated with increasing concentrations of RMC-4550 for 1 h. Cellular lysates were prepared and the levels of RAS-GTP (e) and pERK (f) were determined. RAS-GTP levels in CAL-12T, NCI-H1666 and NCI-H508 cells were inhibited in a concentration-dependent manner by RMC-4550. RMC-4550 produced a concentration-dependent reduction in pERK levels in CAL-12T, NCI-H1666 and H508 cells with geometric mean IC 50 values of 7 nM, 6 nM and 4 nM respectively (n = 2 biologically independent observations for RAS-GTP, and n = 4 biologically independent experiments for pERK, in duplicate; the data represent the mean ± s.e.m. for RAS-GTP and the mean ± s.d. for pERK.) Source data are provided in Supplementary Table 9 .
to RMC-4550-induced suppression of RAS-GTP and pERK levels ( Supplementary Fig. 4b,c ). These data are consistent with the more uniform responses of cancer cell lines bearing KRAS G12C mutations to RMC-4550-mediated growth inhibition and the variable responses of cells bearing KRAS G12D and KRAS G12V mutations. Collectively, these data demonstrate that certain oncogenic Gly 12 variants of KRAS remain dependent on SHP2-mediated GTP loading to promote downstream signalling and cell proliferation.
RMC-4550 inhibits RAS activation through disruption of key protein interactions.
In light of our findings that SHP2 inhibition can be used to target distinct classes of RAS/MAPK pathway oncoproteins that remain dependent on RAS-GTP loading, we tested whether SHP2-dependent modulation of RAS-GTP levels was due to disruption of core RAS-regulatory processes. First, we mined data from Project DRIVE 35 , in which thousands of genes were systematically depleted across hundreds of cell lines to study genetic dependencies of molecularly defined cancer cell lines. Using a hypothesis-driven approach, we obtained data for 33 genes involved in RTK/RAS/MAPK signalling and calculated a correlation matrix ( Fig. 5a ). Two functional modules were readily apparent-the MAPK signal relay downstream of activated RAS and the RTK/ convergent node module upstream of activated RAS. Furthermore, the most closely correlated knockdowns to PTPN11 (SHP2) are loss of the GEF protein SOS1 (correlation coefficient = 0.51) and of the adaptor protein GRB2, which links RTKs to SOS1-mediated GTP RAS-GTP levels in NCI-H1838 and MeWo cells were inhibited in a concentration-dependent manner by RMC-4550 (n = 2 independent experiments for MeWo and n = 3 independent experiments for NCI-H1838; the data represent the mean ± s.e.m.) The geometric mean IC 50 value for reduction in pERK was 29 nM in NCI-H1838 cells, and 24 nM in MeWo cells (the data are representative of n = 4 biologically independent observations, each performed in technical duplicate; the data represent the mean ± s.d.). Source data are provided in Supplementary Table 9 .
Fig. 4 | SHP2 inhibition suppresses growth and RAS/MAPK signalling in a range of cancer cell lines driven by KRAS G12 mutations. a,b,
Representative KRAS G12C lines, NCI-H358 and MIA PaCa-2, were grown in 2D culture and incubated with increasing concentrations of RMC-4550 for 1 h. Cellular lysates were prepared and the levels of RAS-GTP (a) and pERK (b) were determined. RMC-4550 produced a concentration-dependent reduction in both cellular RAS-GTP and pERK levels. Geometric mean IC 50 values for reduction in pERK in NCI-H358 and MIA PaCa-2 cells were 28 nM and 63 nM respectively (n = 4 independent experiments performed in technical duplicate; the data represent the mean ± s.d. for pERK and the mean ± s.e.m. for RAS-GTP). c, NCI-H358 cells were grown on ULA plates as spheroids. After 5 days in culture, spheroids were treated with RMC-4550 or staurosporine, as a positive control, and assayed for caspase 3/7 activity after 20 h (n = 3 independent observations; the data represent the mean ± s.d.) Source data are provided in Supplementary Table 9 . FLT3  IRS1  PDGFRA  KRAS  IGF1R  RAF1  HRAS  MET  MAPK3  MAP2K1  BRAF  MAPK1  FRS2  GAB2  GAB1  ALK  ERBB2  EGFR  GRB2  PTPN11  SOS1   MAP2K2  NRAS  FLT3  IRS1  PDGFRA  KRAS  IGF1R  RAF1  HRAS  MET  MAPK3  MAP2K1  BRAF  MAPK1  FRS2  GAB2  GAB1  ALK  ERBB2  EGFR  GRB2 Cells were incubated for 1 h with RMC-4550 and stimulated with EGF (50 ng ml −1 ) 5 min before collection. Membrane fractionation was performed by differential lysis and centrifugation of cellular components (C, cytosol; M, membrane). Signal intensity was quantified for SHP2 and GAB1 in the membrane fraction (n = 3 independent biological experiments depicted as normalized intensity for RMC-4550 over the dimethylsulfoxide (DMSO)-treated control; mean ± s.d.). f, A schematic model of the function of SHP2 as a transducer of signals from upstream RTKs to SOS1 for RAS activation. Source data are provided in Supplementary Table 9 . Supplementary Table 9 .
loading of RAS (correlation coefficient = 0.40). In fact, SOS1 and GRB2 are the most closely related gene knockdowns to PTPN11 across all 7,837 genes in the Project DRIVE data set 34 . Consistent with previous work, this analysis suggested that SHP2 is an essential member of a core RAS-regulatory module containing SOS1 and GRB2. Therefore, RMC-4550 may downregulate RAS-GTP by disrupting the SHP2/GRB2/SOS1 module that is required for GTP loading of RAS 37, 38 .
To test this hypothesis, we examined whether a dominant, constitutively active mutant form of SOS1 could confer resistance to RMC-4550-mediated inhibition of RAS/MAPK signalling. Indeed, in HEK293 cells, inducible expression of SOS-F, an established SOS1 mutant in which the carboxy-terminal region containing a GRB2binding site is replaced with the HRAS farnesylation motif that targets the protein constitutively to the plasma membrane 39 , rendered cells insensitive to either EGF stimulation ( Supplementary Fig. 4d ) or SHP2 inhibition of pERK (Fig. 5b) . Expression of SOS-F in NCI-H358 cells also markedly reduced sensitivity to RMC-4550-induced suppression of pERK ( Supplementary Fig. 4e ). These data show that the effects of SHP2 inhibition can be bypassed by constitutive and regression = − 34%, respectively (***P = 0.00223 for 10 mg kg −1 ; ***P = 3.76 × 10 −5 for 30 mg kg −1 ) (a), LUN037 (BRAF N581D ) at 10 and 30 mg kg −1 , TGI = 48% and 71%, respectively (**P = 0.00575) (b), TH77 (NF1 S1759C ) at 30 mg kg −1 , TGI = 69% (**P = 0.0050) (c), LUN092 (KRAS G12C ) at 10 and 30 mg kg −1 , TGI = 65% and 96%, respectively (*P = 0.0386; **P = 2.33 × 10 −4 ) (d) and LUN156 (KRAS G12C ) at 10 and 30 mg kg −1 , TGI = 75% and 89%, respectively (***P = 1.03 × 10 −3 for 10 mg kg −1 ; ***P = 3.75 × 10 −6 for 30 mg kg −1 ). Statistical test: ordinary one-way ANOVA with post-hoc Tukey's test. The data represent the mean ± s.e.m. f, RAS-GTP levels were assessed by RAS-GTP enzyme-linked immunosorbent assay (ELISA) in tumour lysates derived from vehicle-and RMC-4550-treated animals (n = 3 independent samples each). Durable suppression of RAS-GTP was observed in RMC-4550-treated tumours collected at the endpoint. The data represent the mean ± s.d. for each individual animal measured across two technical replicates, *P = 0.0157 by unpaired t-test (two-tailed). Source data are provided in Supplementary Table 9 .
activation of SOS1 and that SOS1 therefore functions downstream of (or in parallel to) SHP2. Next, we examined whether RMC-4550 modulated the physical association of SHP2 with other proteins required for RAS activation. We observed by immunoprecipitation experiments that RMC-4550 blunted SHP2's interaction with the RTK-proximal scaffolding protein GAB1 (Fig. 5c,d) , as well as GAB1's interaction with GRB2 ( Fig. 5d ). We then tested whether this disruption of these key protein interactions was associated with diminished recruitment of the proteins to the cell membrane, which is necessary for productive GEF-mediated RAS-GTP loading and subsequent downstream pathway signalling 40, 41 . We observed by cellular membrane fractionation studies that RMC-4550 caused a significant reduction in the levels of SHP2, GAB1 and GRB2 at the cell membrane (Fig. 5e) , extending a recent report based on immunofluorescence imaging 42 . Allosteric inhibition of SHP2 may thus interfere with the formation of a multi-protein complex that is assembled at RTKs located in the cell membrane through disruption of productive binding of SHP2 with adaptor proteins such as GAB1. This effect of SHP2 inhibition interferes with the formation of a productive protein complex that is essential for RAS-GTP loading and activation (Fig. 5f ). Our mechanistic insights extend the understanding of how SHP2 interacts with other proteins, such as the GAB1-GRB2-SOS1 complex, that are important regulators of RAS-GTP levels in cells.
SHP2 inhibition by RMC-4550 drives tumour growth inhibition and tumour regressions in vivo.
Building on our in vitro findings, we tested whether the sensitivity to SHP2 inhibition observed in NF1 LOF and KRAS G12C mutant cell lines was recapitulated in vivo. Daily oral dosing of RMC-4550 resulted in dose-dependent tumour growth inhibition in two NF1 LOF -driven cell line-derived xenograft (CDX) models, MeWo and NCI-H1838, with tumour regression observed in the latter (Fig. 6a,b) . Similarly, we observed dosedependent anti-tumour activity with daily oral dosing of RMC-4550 in both the KRAS G12C NCI-H358 and MIA PaCa-2 xenograft tumour models in immune-deficient mice (Fig. 6c,e and Supplementary  Tables 6 and 7) , with tumour growth inhibition observed at all doses. To link the observed anti-tumour activity with pharmacodynamic modulation of the RAS/MAPK pathway, we measured the effects of RMC-4550 on pERK levels in tumour lysates in the KRAS G12C models. We observed time-dependent suppression of pERK in tumour lysates over a period of 24 h following a single dose of RMC-4550 in the NCI-H358 xenograft model ( Fig. 6d ) and in the MIA PaCa-2 model following the final dose of a repeat dose study ( Fig. 6f,g) . Analysis of pERK inhibition, relative to the plasma concentration of unbound RMC-4550, revealed an in vivo half-maximum effective concentration (EC 50 ; 49 nM) strikingly similar to that observed in vitro (63 nM) ( Fig. 6g ).
Consistent with our in vitro observations, daily oral dosing of RMC-4550 (at a dose of 30 mg kg −1 ) in two CDX models of RMC-4550-insensitive KRAS mutations, HCT-116 (KRAS G13D , CRC) and CALU-6 (KRAS Q61K , NSCLC), failed to induce significant tumour growth inhibition ( Supplementary Fig. 5a,b ). All doses of RMC-4550 were well tolerated for the duration of each study ( Supplementary  Figs. 5c,d and 6a-d) .
To extend our studies into additional clinically relevant in vivo models, we evaluated the response to RMC-4550-mediated SHP2 inhibition in patient-derived xenograft (PDX) models. Two PDX models of BRAF mutant NSCLC, LUN023 and LUN037, were tested. LUN023 carries the previously described class 3 mutation BRAF D594N9 , while LUN037 carries BRAF N581D , a known class 3 variant position and established RASopathy mutant substitution 43 . As predicted for this class of semi-autonomous driver of RAS/MAPK signalling, we observed dose-dependent tumour growth inhibition on repeated daily oral dosing of RMC-4550 in both models (Fig. 7a,b ). Further, we tested RMC-4550 in three additional PDX models of NSCLC and confirmed NF1 LOF and KRAS G12C mutations as genotypic biomarkers of sensitivity to SHP2 inhibition in these PDXs, validating our in vitro and in vivo CDX model findings ( Fig. 7c-e ). All doses of RMC-4550 were well tolerated for the duration of each study ( Supplementary Fig. 6e-i) . In the NF1 LOF model, we observed significant suppression of RAS-GTP and tumour necrosis in treated relative to control tumours at the study endpoint ( Fig. 7f and Supplementary Fig. 7b ). While not a head-to-head comparison, we noted that the effects of SHP2 inhibitor treatment we observed here appear to be similar to those observed following treatment of these same KRAS G12C PDX models with the KRAS G12C covalent inhibitor ARS-1620 44 .
Discussion
In summary, we report a potent and selective SHP2 allosteric inhibitor, RMC-4550, which we have used to uncover a previously unrecognized dependence of class 3 BRAF, NF1 LOF and KRAS G12 mutants on SHP2-mediated upstream signals for cell growth. Our data indicate that these RAS pathway oncoproteins appear to amplify, rather than bypass, the physiologic control mechanisms regulating RAS-GTP levels and pathway output. This paradigm contrasts with the traditional model in which RAS pathway oncoproteins are constitutively active. Instead, our data support an emerging framework in which certain oncoproteins are semi-autonomous, rather than fully autonomous, cancer drivers.
Our mechanistic findings provide insight into how SHP2 functions to promote RAS/MAPK signalling, cellular proliferation and cancer by coordinating adaptor protein and RAS GEF recruitment to the cell membrane where RTK activation occurs. Our data prompt additional, future investigations to more fully define the role of SHP2 in linking RTK activation to downstream RAS/MAPK pathway activation. These efforts are now enabled by the development of potent and selective allosteric inhibitors of SHP2 such as RMC-4550.
Our findings have immediate translational implications. The particular forms of RAS pathway oncoproteins we study herein occur frequently in NSCLC 3, 45 and are currently pharmacologically intractable. Our data suggest SHP2 inhibition as a promising therapeutic strategy in patients with tumours harbouring these semiautonomous, non-RTK oncoproteins.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41556-018-0169-1.
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Methods Discovery of RMC-4550. RMC-4550 was identified through evaluation of our collection of methyl-pyrazine compounds. Three hundred and nine of these compounds are exemplified in a published patent application 46 , which contains the relevant structure-activity-relationship information, and listed in the file WO-2018013597_list.xls in the Supplementary Information. SHP2 inhibition values for exemplary compounds are also provided in the file WO-2018013597_list.xls in the Supplementary Information. Detailed information about the structure, potency, selectivity and pharmacokinetic properties of RMC-4550 is provided in Fig. 1 and Supplementary Tables 1-3, 6 and 7 .
Cell lines and reagents. Cells were grown in appropriate medium and supplemented with 10% fetal bovine serum (Cellgro) and 1% penicillin/ streptomycin (Gibco) unless directed otherwise. Cells were maintained at 37 °C in a humidified incubator at 5% CO 2 . For a complete list of cell lines and sources, see Reporting Summary. Table 8 for a complete list of antibodies.
Antibodies. See Supplementary
Spheroid formation and proliferation. Two thousand five hundred cells per well
were seeded in round-bottom ultralow-attachment 96-well plates (Corning) in growth medium supplemented with 10% fetal bovine serum and 1% penicillin/ streptomycin, and incubated for 72 h at 37 °C in 5% CO 2 . Spheroid formation was confirmed visually, and spheroids were treated in duplicate with serial threefold dilutions of RMC-4550 in complete growth medium (final DMSO concentration = 0.1%). Following drug exposure for five days, cell viability in spheroids was determined using the CellTiter-Glo assay kit (Promega), following the manufacturer's instructions. Luminescence was read in a SpectraMax M5 Plate Reader (Molecular Devices). Assay data were normalized to DMSO values, and EC 50 values were determined using a four-parameter concentration-response model in GraphPad Prism 7. The figures show the mean ± standard deviation of duplicate values from representative experiments.
Analysis of ERK1/2 phosphorylation. ERK1/2 phosphorylation at Thr202/ Tyr204 was assayed using the AlphaLISA SureFire Ultra HV pERK Assay Kit (Perkin Elmer). Twenty-four hours before the assay, 20,000 cells per well were plated in clear 96-well plates, in biotin-free medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin, and incubated overnight at 37 °C in 5% CO 2 . One hour before treatment with RMC-4550, medium was replaced with biotin-free medium supplemented with 0.02% bovine serum albumin and 1% penicillin/streptomycin. Cells were incubated at 37 °C in 5% CO 2 for 1 h. Cells were then exposed to serial threefold dilutions of RMC-4550 diluted in biotinfree medium supplemented with 0.02% bovine serum albumin and 1% penicillin/ streptomycin (final DMSO concentration equivalent to 0.1%). Cells were incubated in the presence of RMC-4550 for 1 h at 37 °C in 5% CO 2 . Cellular lysates were prepared and pERK levels were determined according to the manufacturer's protocol. Samples were read using an EnVision Multilabel Plate Reader (Perkin Elmer) using standard AlphaLISA settings. The assay data were plotted and EC 50 values were determined using a four-parameter concentration-response model in GraphPad Prism 7. The data in the figures are mean ± standard deviation of duplicate values from representative experiments.
Analysis of RAS-GTP levels.
The levels of activated RAS-GTPase were determined using the Ras GTPase ELISA Kit (Abcam), similar to a previously published method 47 . Briefly, 1 × 10 6 cells were seeded in medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin in 10 cm tissue culture dishes, and incubated for 48 h at 37 °C in 5% CO 2 . Cells were then treated with RMC-4550 diluted in medium supplemented with 0.02% bovine serum albumin and 1% penicillin/streptomycin to a final DMSO concentration equivalent to 0.1%. Cells were incubated in the presence of RMC-4550 for 1 h at 37 °C in 5% CO 2 . Following this exposure period, medium was removed and cells were washed once in ice-cold PBS. Cells were immediately lysed in ice-cold 1× Lysis Buffer (25 mM Tris-HCl, pH 7.2, 150 mM NaCl, 5 mM MgCl 2 , 1% NP-40, 5% glycerol) (Thermo) supplemented with Halt Protease and Phosphatase Inhibitor (EDTA-free) (Thermo), and lysates were cleared by centrifugation at 15,500 × g for 15 min at 4 °C. Protein quantification was performed with the BCA Protein Assay Kit (Pierce), and lysates were diluted to a final concentration of 1 mg ml −1 . Cell lysates were prepared and levels of RAS-GTP were determined using a plate-based ELISA as described in the manufacturer's protocol. The data in the figures are the mean ± standard deviation of duplicate values from representative experiments.
RAS-mutant cancer cell panel screen.
Cell lines were maintained in growth medium supplemented with 10% fetal bovine serum and 1% penicillin/ streptomycin at 37 °C, 5% CO 2 . For each line, two 96-well plates were seeded with 600 cells per well suspended in 0.65% methylcellulose. Plates were incubated at 37 °C, 5% CO 2 . The following day, one of the plates for each line was used to obtain initial (T = 0) readings using the CellTiter-Glo (CTG) assay kit (Promega), following the manufacturer's instructions. Luminescence was read in an EnVision Multilabel Plate Reader (Perkin Elmer). Serial threefold dilutions of RMC-4550 were prepared in growth medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (final DMSO concentration = 0.1%) and added to each well. Cells were incubated for seven days, and the number of viable cells was quantified using the CTG assay, as above. Day 7 (T = 7) values for a given RMC-4550 concentration X were individually normalized against T = 0 values according to the formula: Normalized value = ((S7[X] − S0)/(S7[DMSO] − S0)) × 100, where S7 is the CTG signal at T = 7, and S0 is the CTG signal at T = 0. Normalized data were imported into Prism 7 (GraphPad) software, and IC 50 values were calculated by fitting to a four-parameter concentration--response model and determining the RMC-4550 concentration resulting in 50% absolute inhibition. Activated caspase 3/7 assay in spheroids. H358 cells were grown into spheroids by seeding 5,000 cells per well in round-bottom ultralow attachment 96-well plates (Corning) in RPMI medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin and incubated at 37 °C in 5% CO 2 for 5 days to allow for spheroid formation. Spheroid formation was confirmed visually. Spheroids were treated in triplicate with RMC-4550, staurosporine (Sigma) or DMSO (Sigma) (0.1% final), diluted in RPMI medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin, and incubated at 37 °C in 5% CO 2 for 20 h. Caspase 3/7 activity was measured using the Caspase-Glo 3/7 Assay System (Promega), following the manufacturer's instructions. Luminescence was read in an EnVision Multilabel Plate Reader (Perkin Elmer).
SHP2 and SOS1 knockdown. For stable and lentivirally transfected shRNA-based knockdown experiments, viruses were generated in HEK293T cells transfected with lentiviral packaging vectors along with vectors expressing pLKO-shSHP2 and pLKO-shSOS1 (MISSION TRC shRNA) using Fugene6 (Promega). Two distinct hairpins per gene were chosen for the experiments. Their sequences are as follows: SHP2-1, 5ʹ -CCGGCGTGTTAGGAACGTCAAAGAACTCGAGTTCTTTGACGT TCCTAACACGTTTTT-3ʹ ; SHP2-2, 5ʹ -CCGGCCCTTGTAAGAAGAAAGGATT CTCGAGAATCCTTTCTTCTTACAAGGGTTTTT-3ʹ ; SOS1-1, 5ʹ -CCGGGCACT TTATTTGCAGTCAATACTCGAGTATTGACTGCAAATAAAGTGCTTTTTG-3ʹ ; SOS1-2, 5ʹ -CCGGCCACAGATGTTTGCAGTGTATCTCGAGATACACTGCAAA CATCTGTGGTTTTTG-3ʹ . Viral supernatant collected from confluent monoculture was filtered and used to infect NCI-H358 lung cancer cells. A total of 0.5 × 10 6 NCI-H358 cells were seeded in one well of a 6-well chamber and allowed to grow for 24 h. The next day, cells were incubated with a 1:1 mixture of normal growth medium and viral supernatant collected earlier from HEK293T cells, which contains lentiviruses producing shRNAs against SHP2 and SOS1. Polybrene was added at 8 µ g ml −1 concentration. This was followed by a plate centrifugation at 3,000 RCF for 90 min (Sorvall RT7 plus). Subsequently, cells were selected for transduced cells using 1 µ g ml −1 puromycin for 48 h. Sensitivities of the cells to the SHP2 and SOS1 knockdown were determined using crystal violet staining assays via spectrophotometric intensity. Collected lysates from parallel experiments were probed for knockdown efficiency, pERK level using western blot and RAS-GTP level using affinity purification followed by immunoblot. SHP2 WT and SHP2 E76K rescue experiments. SHP2 WT and SHP2 E76K constructs were synthesized (Atum) and stable expression in NCI-H358 (KRAS G12C ) cells, NCI-H1838 (NF1 LOF ) cells and NCI-H508 (Class 3 BRAF) cells was achieved by lentiviral transduction. Cell proliferation of parental and lentiviral-transduced cells was performed as outlined above (Spheroid formation and proliferation). For pERK analysis, 5 × 10 5 cells per well were seeded in 6-well format. After 24 h, cells were treated for 90 min with DMSO or RMC-4550 (1 µ M), respectively. Cell lysates were prepared and analysed by western blotting using antibodies against pERK, ERK, SHP2 and HSP90 (Cell Signaling Technologies).
Sensitivity analysis in RASless MEFs.
Hras −/− , NRas −/− , Kras −/− mouse embryonic fibroblasts (RASless MEFs) were acquired from the NCI RAS Initiative 48 , namely KRAS-4B WT-, G12C-, G12D-, G12V-and Q61H-as well as BRAF V600E -expressing cells. For each line and treatment, 4 × 10 5 cells were seeded per 10 cm dish and treated with DMSO or RMC-4550 (1 µ M) for 24 h. Cell lysates were prepared and RAS-GTP levels were determined by RAS-GTP ELISA (Abcam) or RAF-RBDmediated pulldown using the RAS Pull-down Activation Assay Biochem Kit (Cytoskeleton), respectively. Western blot analysis was conducted on pulldown fractions and whole-cell lysates using antibodies against RAS (Millipore), pERK (Cell Signaling Technologies), ERK (Cell Signaling Technologies) and actin (Sigma Aldrich).
Knockdown of NF1 in BEAS-2B cells.
Knockdown of NF1 was achieved by lentiviral transduction of BEAS-2B cells with MISSION shRNA (Sigma Aldrich) having the following sequence: 5ʹ -CCGGCCATGTTGTAATGCTGCACTTCTC GAGAAGTGCAGCATTACAACATGGTTTTTG-3ʹ and being expressed from a pLKO.1-puro plasmid backbone. One day after lentiviral transduction, cells were selected via treatment with 1 µ g ml −1 puromycin for 48 h. For RAS-GTP analysis, cells were seeded at a density of 1 × 10 6 cells per 10 cm dish. One day post seeding, cells were starved in serum-free medium for 18 h and treated with either vehicle (DMSO) or RMC-4550 (1 µ M) for 1 h. Cells were stimulated with 100 ng ml −1 Formulation and pharmacokinetics. RMC-4550 was formulated in sulfobutylether betacyclodextrin (Captisol)/50 mM sodium acetate pH 4.6 (10%/90%, w/v%). Plasma samples for PK analysis were collected in a composite manner with three animals per time point. The plasma concentration of RMC-4550 was measured by a liquid chromatography tandem mass spectrometry method using positive electrospray ionization in multiple reaction monitoring mode. Plasma samples were extracted by protein precipitation using acetonitrile containing an internal standard. After vortexing and centrifugation, the supernatant was injected into an API6500 (AB SCIEX) liquid chromatography tandem mass spectrometry system for quantification. PK parameters were calculated by non-compartmental analysis of the plasma concentration-time profiles using Phoenix 64 (Certara).
Tumour xenograft and in vivo pharmacodynamics.
The study is compliant with all relevant ethical regulations regarding animal research. The animal studies shown in Fig. 6a and Supplementary Fig. 6a were conducted in accordance with approved institutional animal care and use committee (IACUC) protocols at Translational Drug Development, Scottsdale, AZ. The animal studies shown in Fig. 6b-d and Supplementary Figs. 5 and 6b ,c were conducted in accordance with approved IACUC protocols at WuXi Apptec, Suzhou, China. The animal studies shown in Fig. 6e-g and Supplementary Fig. 6d were conducted in accordance with approved IACUC protocols at MI Bioresearch, Inc., Ann Arbor, MI. The animal studies shown in Fig. 7a,b,d,e and Supplementary Fig. 6e ,f,h,i were conducted in accordance with approved IACUC protocols at Genendesign, Inc., Shanghai, China. The animal studies shown in Fig. 7c,f and Supplementary Fig. 6g were conducted in accordance with approved IACUC protocols at the University of California, San Francisco, CA. Female (6) (7) (8) week old) athymic nude mice were implanted with NCI-H358 (Balb/c strain background), MIA PaCa-2 (NCR nude strain background), MeWo (SCID Beige strain background), NCI-H1838 (SCID Beige strain background), HCT-116 (Balb/c strain background) or CALU-6 (Balb/c strain background) tumour cells subcutaneously in the flank. Once tumours reached an average size of ~200 mm 3 (NCI-H358, MIA PaCa-2), 100 mm 3 (MeWo), 400 mm 3 (NCI-H1838) or 150 mm 3 (HCT-116, CALU-6), administration of RMC-4550 (3 to 60 mg kg −1 , by oral administration) or vehicle (Captisol/50 mM acetate buffer pH 4.6 (10%/90%, w/v)) was initiated. RMC-4550 was dosed daily via oral gavage at specified doses and was well tolerated ( Supplementary Figs. 9-11 ). For pharmacodynamics studies, animals received a single dose of either RMC-4550 or vehicle, followed by euthanasia at a specified time (2, 8 or 24 h post-dose). At this time, tumours were collected, a portion minced and snap-frozen immediately for protein isolation and another portion fixed in 10% neutral buffered formalin before processing into paraffin blocks. Tumour lysates were prepared and pERK 1/2 evaluation was carried out using the Meso-Scale Discovery kit K15107D according to the manufacturer's instructions.
PDXs. The study is compliant with all relevant ethical regulations regarding research involving human participants. For generation of the TH77 PDX model, informed consent was obtained from the patient as per an open IRB-approved protocol at the University of California, San Francisco. Tumours were implanted in SCID mice (Taconic Biosciences). LUN023, LUN037, LUN092 and LUN156 were obtained with informed consent under approval by the Shanghai Changhai Hospital Ethics Committee. The models were derived at Genendesign, Shanghai, China, implanted in athymic Balb/C nude mice, and used at low passage for the experiments described herein. Once tumours reached an average volume of ~200 mm 3 , mice were treated with RMC-4550 (10 or 30 mg kg −1 , by oral administration, n = 10) or vehicle (2% HPMC E-50, 0.5% Tween-80 in 50 mM sodium citrate buffer, pH 4.0, n = 10), dosed daily via oral gavage. Animals were euthanized when a mean tumour volume of ~1,000-1,600 mm 3 was reached in the vehicle cohort. To allow pharmacodynamics analysis at the endpoint, animals received a final dose of RMC-4550 or vehicle, respectively, and were euthanized at 2, 8 or 24 h post dosing. All tumours were split in two pieces and either snapfrozen and stored at − 80 °C, or fixed in 10% neutral buffered formalin for 72 h before being transferred to 70% ethanol and stored at 4 °C. For RAS-GTP analysis, frozen tumours were minced using a liquid-nitrogen-cooled mortar and pestle. Cell lysates were prepared and RAS-GTP levels were determined by RAS-GTP ELISA (Abcam). For immunohistochemical analysis, fixed tumour samples were sectioned and stained with haematoxylin and eosin.
Phosphatase selectivity panel.
A panel of 12 protein tyrosine phosphatases was expressed with 6-His tags in Escherichia coli and purified using standard Ni 2+ affinity purification procedures. Two protein serine/threonine phosphatases (PP1 and PP2A) were also used and obtained from SignalChem. The inhibition assays for each phosphatase were similar to the conditions described for the SHP2 full length and catalytic enzymes, except that the assay was performed in 384-well black polystyrene plates (Corning) with a total well volume of 50 µ l, and fluorescence was read as an endpoint after a 5-min incubation at room temperature. The following additional enzyme-specific changes were made. The enzyme concentration was 0.3 nM (PTP1b, HePTP, Lyp, CD45 and PTPRB), 125 nM (LMPTPA and PRL1), 15 nM (LMPTPB), 5 nM (DUSP22 and STEP), 1.6 nM (PP1), 0.5 nM (PP2A), 0.25 nM (SHP1 catalytic domain) and 0.2 nM (SHP1 full length). The reaction time for PP1 and DUSP22 was 20 min, and 90 min for PRL1. For PP1 and PP2A, the EDTA in the assay buffer was replaced with 5 mM MnCl 2 . The assay for fulllength SHP1 was similar to the assay for full-length SHP2, except that the enzyme was activated with a synthetic activating peptide with sequence H 2 N-LN(pY) AQLWHA(PEG8)LTI(pY)ATIRRF-amide at 250 nM.
Kinase selectivity panel. Kinase selectivity was determined using the ScanMax panel (DiscoverX).
Cellular targets selectivity panel. The off-target profile was determined using Eurofins SafetyScreen44 panel, Eurofins (Eurofins Cerep).
Statistics and reproducibility.
Quantitative data are presented as the mean ± standard deviation (s.d.) or the standard error of the mean (s.e.m.), as specified in the figure legends. Statistical tests were performed using GraphPad Prism 7.0. Two-sided Student's t-tests were used for comparisons of the means of data between two groups, unless otherwise specified. For comparisons among multiple independent groups, one-way ANOVA with post-hoc Tukey's test was used. For animal studies, animals were randomized before treatments, and all animals treated were included for the analyses. When representative experiments are shown, these represent one out of at least two independent experiments with similar results.
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Data collection
Gene signatures were downloaded from the Project Drive data portal (https://oncologynibr.shinyapps.io/drive/) and assembled into a matrix. Correlation analysis was conducted in R and heatmaps generated with the pheatmap package.
Data analysis
All statistical analyses and plots were generated using Graphpad Prism 7. Correlation analysis was conducted in R and heatmaps were generated with the pheatmap package. Images were analyzed using Fiji image analysis software.
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Sample size
Animal study sample sizes were determined based on statistical power analysis devised to detect significant differences of 30% tumor growth inhibition.
Data exclusions No data were excluded from the analyses.
Replication
All experiments were successfully replicated.
Randomization Tumor-bearing animals in efficacy studies were subject to block randomization resulting in equally sized groups with the same mean tumor volumes.
Blinding
Data acquisition in the studies, including animal experiments, was conducted in a blinded manner.
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Validation
All antibodies used were validated by the respective commercial source for the application used in this manuscript.
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Cell line source(s)
The following cell lines were used in the study -A-375, NCI-H1755, CAL-12T, NCI-H1666, NCI-H508, SK-MEL-113, MeWo, HCC1359, NCI-H1838, YUDAB, M308, YUHEF, YUTOGS, NCI-H358, MIA PaCa-2, HEK293. All were purchased from the American Type Culture Collection (ATCC) unless otherwise indicated. Cells were maintained at 37°C in a humidified incubator at 5% CO2. Cells were grown in appropriate media as recommended by ATCC, and supplemented with 10% fetal bovine
